首页> 外文期刊>Journal of Clinical Epidemiology >Systematic review on costs and resource use of randomized clinical trials shows a lack of transparent and comprehensive data
【24h】

Systematic review on costs and resource use of randomized clinical trials shows a lack of transparent and comprehensive data

机译:随机临床试验的性价比和资源使用的系统审查显示缺乏透明和综合数据

获取原文
获取原文并翻译 | 示例
           

摘要

ObjectivesRandomized clinical trials (RCTs) are costly. We aimed to provide a systematic overview of the available evidence on resource use and costs for RCTs to support budget planning. Study Design and SettingWe systematically searched MEDLINE, EMBASE, and HealthSTAR from inception until November 30, 2016 without language restrictions. We included any publication reporting empirical data on resource use and costs of RCTs and categorized them depending on whether they reported (i) resource and costs of all aspects at all study stages of an RCT (including conception, planning, preparation, conduct, and all tasks after the last patient has completed the RCT); (ii) on several aspects, (iii) on a single aspect (e.g., recruitment); or (iv) on overall costs for RCTs. Median costs of different recruitment strategies were calculated. Other results (e.g., overall costs) were listed descriptively. All cost data were converted into USD?2017. ResultsA total of 56 articles that reported on cost or resource use of RCTs were included. None of the articles provided empirical resource use and cost data for all aspects of an entire RCT. Eight articles presented resource use and cost data on several aspects (e.g., aggregated cost data of different drug development phases, site-specific costs, selected cost components). Thirty-five articles assessed costs of one specific aspect of an RCT (i.e., 30 on recruitment; five others). The median costs per recruited patient were USD 409 (range: USD 41–6,990). Overall costs of an RCT, as provided in 16 articles, ranged from USD 43–103,254 per patient, and USD 0.2–611.5 Mio per RCT but the methodology of gathering these overall estimates remained unclear in 12 out of 16 articles (75%). ConclusionThe usefulness of the available empirical evidence on resource use and costs of RCTs is limited. Transparent and comprehensive resource use and cost data are urgently needed to support budget planning for RCTs and help improve sustainability.
机译:玻美疗效临床试验(RCT)是昂贵的。我们旨在提供有关RCT资源使用和费用的可用证据,以支持预算规划的可用证据。从开始到2016年11月30日没有语言限制,学习设计和设置系统地搜索了Medline,Embase和Healthstar,直到2016年11月30日。我们包括任何出版物报告了关于RCT的资源使用和成本的经验数据,并根据他们是否报告(i)RCT所有研究阶段的所有方面的资源和成本(包括概念,规划,准备,行为)的资源和成本进行分类最后患者完成RCT后的任务); (ii)在若干方面,(iii)在一个方面(例如,招聘);或(iv)对RCT的总成本。计算了不同招聘策略的中位数。描述了其他结果(例如,总体成本)是描述的。所有成本数据都被转换为2017年USD?结果总共有56条报告的RCT的成本或资源使用的文章。没有一篇文章为整个RCT的所有方面提供了经验资源使用和成本数据。八篇文章在几个方面提出了资源使用和成本数据(例如,不同药物开发阶段的聚合成本数据,特定于特定的成本,选定的成本组件)。三十五篇文章评估了RCT的一个特定方面的成本(即,招聘30;五种)。每名招募患者的中位数为409美元(范围:41-6,990美元)。如16条文章所提供的RCT的总体成本范围从43-103,254美元,每次RCT的0.2-611.5 MIO,但收集这些整体估计的方法仍不清楚,其中12篇文章中的12篇(75%)。结论可用的经验证据对资源使用和RCT成本的有用性有限。迫切需要透明和综合资源使用和成本数据来支持RCT的预算规划,并有助于提高可持续性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号